UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center
单位:北卡罗来纳大学/德克萨斯大学国家临床试验网络集团综合转化科学生产和咨询中心
基本信息
- 批准号:10353405
- 负责人:
- 金额:$ 66.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-13 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccreditationAddressAdoptionB-Cell Antigen ReceptorBase SequenceBig DataBiological AssayBiological MarkersCLIA certifiedCancer PatientCellsCenter for Translational Science ActivitiesClinicClinicalClinical DataClinical TrialsClinical Trials Cooperative GroupClonalityComplexConsultationsDNADNA SequenceDNA Sequence AlterationDNA copy numberDNA sequencingDataData AnalysesData MartDiagnosisDiseaseEquilibriumExpression ProfilingFormalinFreezingFundingGene ExpressionGene Expression ProfilingGenomic medicineGenomicsGenotypeGoalsGrantHeadHereditary Malignant NeoplasmHumanImmuneImmune systemImmunotherapyInfrastructureInstitutionLaboratoriesLaboratory StudyLocationMalignant NeoplasmsMassive Parallel SequencingMeasuresMethodsMolecular TargetMutationNational Clinical Trials NetworkNeoadjuvant TherapyNucleic AcidsParaffin EmbeddingPatientsPharmaceutical PreparationsPharmacogenomicsPloidiesPrecision Medicine InitiativePredispositionPrivacyProcessProductionRNAReproducibilityResearch PersonnelReverse Transcriptase Polymerase Chain ReactionRoleSamplingScienceSelection for TreatmentsSequence DeletionSpecimenSpeedStaging SystemStandardizationSyndromeT-LymphocyteTechnical ExpertiseTechniquesTechnologyThe Cancer Genome AtlasTimeTranslational ResearchTumor-infiltrating immune cellsUnited States National Institutes of HealthVariantanalysis pipelinebasebiomarker developmentcancer clinical trialcancer genomeclinical decision-makingclinically relevantcost efficientdata disseminationdata sharingdata submissiondatabase of Genotypes and Phenotypesexomeexperiencegenome-widegenomic datahuman subjectimprovedmRNA sequencingmalignant breast neoplasmnano-stringneoantigensnext generationnext generation sequencingnovelopen datapersonalized medicineprecision medicineprivacy protectionprognosticreceptorsingle-cell RNA sequencingtherapeutic enzymetranscriptometranscriptome sequencingtumortumor microenvironmentwhole genome
项目摘要
In the current era of Precision Medicine, laboratory studies are an integral component of cancer clinical trials.
Amongst the most powerful techniques connecting therapies to specific patients are assays that interrogate
nucleic acids (DNAseq and/or RNAseq), which are now most typically done using massively parallel
sequencing (MPS). RNAseq now offers an extremely powerful approach for querying the tumor genome,
where gene expression profiles have proven value in providing prognostic information, predictive information,
and also critical information on the tumor microenvironment including quantitative measures of immune
infiltrations. In addition, DNA based approaches can also be clinically informative in detecting somatic
sequence alterations (mutations), structural variations (fusions), loss of normal DNA sequences (deletions), or
sequence gains (amplifications). Alternatively, sequencing assays can target DNA from noncancerous cells to
address additional questions including identification of familial predisposition, and genotyping of drug
metabolizing enzymes of therapeutic importance.
Through this Project, the UNC / UTHSC UNITS team will provide high volume clinical grade sequencing in a
regulatory compliant manner from day one of the grant. As a world leader in the production of human RNA-
based cancer data, from both frozen and FFPE, including RNA sequencing and targeted RNA quantification,
RNA-based assays are offered within a compliant setting. We are also highly experienced with common, and
complex, DNA-based assays and offer these as well. Aims 1 and 2 of this proposal involve providing an FDA-
and CAP- compliant mechanism for high sample throughput for RNA- and DNA-sequencing from samples
provided from multi-institutional cooperative group trials. RNA sequencing will be offered in 3 formats, RNA-
Seq, NanoString, and Q-rt-PCR, to allow both comprehensive coverage and inexpensive targeted RNA
profiling. DNA sequencing will be offered for both whole exome and targeted capture by MPS, as well as
quantitative DNA measures by NanoString. The third aim is to develop and provide data sharing formats and
an infrastructure for the proper dissemination of clinical trial sequence-based patient information, which is
needed is this era of Big Data.
在当前的精密医学时代,实验室研究是癌症临床试验不可或缺的组成部分。
在将治疗与特定患者联系起来的最强大的技术中,有一种是询问
核酸(DNAseq和/或RNAseq),现在最典型的是使用大规模并行
测序(MPS)。RNAseq现在为查询肿瘤基因组提供了一种极其强大的方法,
其中基因表达谱在提供预后信息、预测信息、
以及关于肿瘤微环境的关键信息,包括免疫的定量测量
渗透。此外,基于dna的方法在检测体细胞方面也可以提供临床信息。
序列改变(突变)、结构变异(融合)、正常DNA序列丢失(缺失)或
序列增益(放大)。或者,测序分析可以将非癌细胞的DNA定向到
解决其他问题,包括识别家族易感性和药物基因分型
代谢酶具有重要的治疗作用。
通过这个项目,北卡罗来纳大学/UTHSC单位团队将在
从拨款的第一天起就以合规的方式。作为人类RNA生产的世界领先者-
基于来自冷冻和FFPE的癌症数据,包括RNA测序和靶向RNA定量,
基于RNA的检测是在合规的环境中提供的。我们对公共事务也非常有经验,而且
复杂的、基于DNA的分析,并提供这些。该提案的目标1和2涉及提供FDA-
以及符合CAP的机制,用于从样本中进行RNA和DNA测序的高样本吞吐量
由多机构合作团体试验提供。RNA测序将以三种格式提供,RNA-
SEQ、纳米串和Q-RT-PCR,以实现全面覆盖和廉价的靶向RNA
侧写。DNA测序将为MPS的整个外显子组和靶向捕获以及
用纳米线对DNA进行定量测量。第三个目标是开发和提供数据共享格式和
用于适当传播基于临床试验序列的患者信息的基础设施,这是
我们需要的是这个大数据时代。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David N Hayes其他文献
David N Hayes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David N Hayes', 18)}}的其他基金
UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center
单位:北卡罗来纳大学/德克萨斯大学国家临床试验网络集团综合转化科学生产和咨询中心
- 批准号:
9892991 - 财政年份:2019
- 资助金额:
$ 66.33万 - 项目类别:
UNITS: The UNC / UT National Clinical Trials Network Group Integrated Translational Science Production and Consultation Center
单位:北卡罗来纳大学/德克萨斯大学国家临床试验网络集团综合转化科学生产和咨询中心
- 批准号:
10581560 - 财政年份:2019
- 资助金额:
$ 66.33万 - 项目类别:
Development of a Four-Class, Molecular Subtyping Diagnostic for HPV-negative Head and Neck Cancer
开发 HPV 阴性头颈癌的四类分子亚型诊断方法
- 批准号:
9752253 - 财政年份:2017
- 资助金额:
$ 66.33万 - 项目类别:
Development of a Four-Class, Molecular Subtyping Diagnostic for HPV-negative Head and Neck Cancer
开发 HPV 阴性头颈癌的四类分子亚型诊断方法
- 批准号:
10216187 - 财政年份:2017
- 资助金额:
$ 66.33万 - 项目类别:
Network Group Integrated Translational Science Centers Application
网络集团综合转化科学中心申请
- 批准号:
8840915 - 财政年份:2014
- 资助金额:
$ 66.33万 - 项目类别:
Network Group Integrated Translational Science Centers Application
网络集团综合转化科学中心申请
- 批准号:
9235259 - 财政年份:2014
- 资助金额:
$ 66.33万 - 项目类别:
Gene Expression Patterns in Human Tumors Identified Using Transcript Sequencing
使用转录测序鉴定人类肿瘤中的基因表达模式
- 批准号:
7942756 - 财政年份:2009
- 资助金额:
$ 66.33万 - 项目类别:
Gene Expression Patterns in Human Tumors Identified Using Transcript Sequencing
使用转录测序鉴定人类肿瘤中的基因表达模式
- 批准号:
8925212 - 财政年份:2009
- 资助金额:
$ 66.33万 - 项目类别:
Gene Expression Patterns in Human Tumors Identified Using Transcript Sequencing
使用转录测序鉴定人类肿瘤中的基因表达模式
- 批准号:
8537844 - 财政年份:2009
- 资助金额:
$ 66.33万 - 项目类别:
Gene Expression Patterns in Human Tumors Identified Using Transcript Sequencing
使用转录测序鉴定人类肿瘤中的基因表达模式
- 批准号:
8117265 - 财政年份:2009
- 资助金额:
$ 66.33万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 66.33万 - 项目类别:
Research Grant